Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.52 CHF | -0.35% | +1.38% | +16.48% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.48% | 15.15B | |
+19.08% | 43.46B | |
+24.43% | 22.61B | |
+22.78% | 14.83B | |
+57.41% | 13.08B | |
-0.05% | 6.79B | |
-12.44% | 6.72B | |
-8.87% | 5.73B | |
+13.42% | 5.45B | |
+7.14% | 4.68B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Transcript : Sandoz Group AG, Q1 2024 Sales/ Trading Statement Call, May 07, 2024